Patents by Inventor Kurt Leander

Kurt Leander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isoquinolines as IGF-1R inhibitors
    Patent number: 8044067
    Abstract: Compounds of the formula (I): were synthesized. In at least one embodiment, they were found to down-regulate or inhibit the expression or function of the IGF-1 receptor.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: October 25, 2011
    Assignee: Analytecon S.A.
    Inventors: Jan Gunzinger, Kurt Leander
  • Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1 r inhibitors
    Patent number: 7875631
    Abstract: Compounds of the formula (I): where R2, R5, R6 have the meanings as given in the description, and U, V and W, respectively, may be CR2?, CR4? and CR6?, respectively (with the definitions of R2?, R4? and R6? again as in the description), or may be N, were synthesized. They were found to down-regulate or inhibit the expression or function of the IGF-1 receptor.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: January 25, 2011
    Assignee: Analytecon S.A.
    Inventors: Jan Gunzinger, Kurt Leander
  • Isoquinolines Derivatives as Igf-1R Inhibitors
    Publication number: 20090099133
    Abstract: Compounds of the formula (I) were synthesized. They were found to down-regulate or inhibit the expression or function of the IGF-1 receptor.
    Type: Application
    Filed: September 8, 2006
    Publication date: April 16, 2009
    Inventors: Jan Gunzinger, Kurt Leander
  • Isoquinolines as IGF-1R Inhibitors
    Publication number: 20090099229
    Abstract: Compounds of the formula (I): were synthesized. In at least one embodiment, they were found to down-regulate or inhibit the expression or function of the IGF-1 receptor.
    Type: Application
    Filed: September 8, 2006
    Publication date: April 16, 2009
    Inventors: Jan Gunzinger, Kurt Leander
  • Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors
    Publication number: 20070129399
    Abstract: Compounds of the formula (I): where R2, R5, R6 have the meanings as given in the description, and U, V and W, respectively, may be CR2?, CR4? and CR6?, respectively (with the definitions of R2?, R4? and R6? again as in the description), or may be N, were synthesized. They were found to down-regulate or inhibit the expression or function of the IGF-1 receptor.
    Type: Application
    Filed: March 12, 2004
    Publication date: June 7, 2007
    Inventors: Jan Gunzinger, Kurt Leander
  • Podophyllotoxin preparation containing triglycerides
    Patent number: 6440428
    Abstract: The invention refers to new pharmaceutical preparations for the treatment of psoriasis and condyloma acuminata, and containing podophyllotoxin in combination with a liquid triglyceride.
    Type: Grant
    Filed: September 27, 1993
    Date of Patent: August 27, 2002
    Assignee: Analytecon SA
    Inventors: Kurt Leander, Jan Gunzinger, Börje Rosen
  • Use of lignan derivatives for the preparation of pharmaceutical compositions for the treatment of states of amyloidosis
    Patent number: 5637571
    Abstract: This invention relates to the treatment of a host afflicted with a state of secondary amyloidosis using certain acetals of podophyllotoxin-.beta.-D-glucopyranoside.
    Type: Grant
    Filed: May 10, 1996
    Date of Patent: June 10, 1997
    Assignees: Conpharm AB, Analytecon SA
    Inventors: Borje Rosen, Kurt Leander
  • Medicinal uses for podophyllotoxins
    Patent number: 4788216
    Abstract: The invention relates to compounds consisting of podophyllotoxin and its derivatives of the formula ##STR1## wherein R.sub.1 is H or OH and R.sub.2 is H or CH.sub.3, for treatment of psoriasis, malaria and rheumatoid arthritis and to a method for their preparation. Furthermore, the invention concerns the use of the compounds for treatment of said states of illness, as well as the use of said compounds for the preparation of pharmacological compositions for the treatment of said states of illness.
    Type: Grant
    Filed: August 28, 1986
    Date of Patent: November 29, 1988
    Assignee: Conpharm AB
    Inventors: Kurt Leander, Borje Rosen